lanicemine
Sign in to saveAlso known as AR-R15896AR, ARL 15896, AZD-6765, AZD6765
Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.
== See also == 4-Chlorokynurenine AD-1211 Apimostinel CERC-301 Diphenidine Ephenidine Esketamine Lefetamine Memantine Methoxphenidine MT-45 Rapastinel
Excerpted from Wikipedia’s “lanicemine” article, available under the CC BY-SA 4.0 licence.